CAT
Caterpillar Inc.
CAT has a slight edge over CPRT overall, supported by stronger modeled upside and stronger fundamentals.
CPRT
Copart, Inc.
CPRT offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
CAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
CAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
CPRT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Strong |
CPRT's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
CAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $380 | -37% |
| Fair | 18x | $461 | -24% |
| Forward | 20x | $605 | — |
| Current | 24x | $605 | — |
| Expensive | 33x | $840 | +39% |
Historical ranges are pointers, not guarantees.
CAT's PE is in its expensive range at 24x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its fair range.
CPRT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $32.00 | — |
| Current | 21x | $32.00 | — |
| Cheap | 24x | $37.74 | +18% |
| Fair | 34x | $53.05 | +66% |
| Expensive | 39x | $60.99 | +91% |
Historical ranges are pointers, not guarantees.
CPRT has the edge over CAT in the historical PE scenario, which offers more potential upside but is not a forecast.
CAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Moderate | |
| Low |
CAT has the edge over CPRT on the outlook, with more favorable profitability expectations.
CPRT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Weakening | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for CPRT, but weaker profitability.
CAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $30.32 | +19% |
| Q3 2026 | $25.48 | +31% |
| Q2 2026 | $23.23 | +18% |
| Q1 2026 | $20.08 | -2% |
| Q4 2025 | $18.81 | -15% |
| Q3 2025 | $19.46 | -9.7% |
| Q2 2025 | $19.64 | -10% |
| Q1 2025 | $20.50 | -7.4% |
| Q4 2024 | $22.05 | +9.6% |
CAT earned $25.48 per share over the past year, up 31% from the year before.
CPRT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.66 | +7% |
| Q3 2026 | $1.55 | -2.5% |
| Q2 2026 | $1.60 | +4.6% |
| Q1 2026 | $1.59 | +6% |
| Q4 2025 | $1.63 | +14% |
| Q3 2025 | $1.59 | +14% |
| Q2 2025 | $1.53 | +7.7% |
| Q1 2025 | $1.50 | +7.9% |
| Q4 2024 | $1.43 | +5.1% |
CPRT has the edge over CAT on earnings, with more consistent year-over-year improvement.
CAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7B | +17% |
| Q2 2026 | $20.5B | +24% |
| Q1 2026 | $17.4B | +22% |
| Q4 2025 | $19.1B | +18% |
| Q3 2025 | $17.6B | +9.5% |
| Q2 2025 | $16.6B | -0.7% |
| Q1 2025 | $14.2B | -9.8% |
| Q4 2024 | $16.2B | -5% |
CAT's revenue has grown year over year for five quarters in a row: $20.7B last quarter, up 17% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +3.1 points |
| Q2 2026 | 21% | +3.6 points |
| Q1 2026 | 18% | -0.4 points |
| Q4 2025 | 14% | -4.1 points |
| Q3 2025 | 17% | -2.2 points |
| Q2 2025 | 17% | -3.6 points |
| Q1 2025 | 18% | -4.2 points |
| Q4 2024 | 18% | -0.3 points |
CAT's operating margin was 20% last quarter, up 3.1 points from the same quarter a year ago.
CPRT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.2B | +2.4% |
| Q2 2026 | $1.2B | +2.1% |
| Q1 2026 | $1.1B | -3.6% |
| Q4 2025 | $1.2B | +0.7% |
| Q3 2025 | $1.1B | +5.2% |
| Q2 2025 | $1.2B | +7.5% |
| Q1 2025 | $1.2B | +14% |
| Q4 2024 | $1.1B | +12% |
CPRT's revenue grew through 2024 and has held roughly level since: $1.2B last quarter, up 2.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -4.7 points |
| Q2 2026 | 38% | +0.3 points |
| Q1 2026 | 35% | -2 points |
| Q4 2025 | 37% | +1.9 points |
| Q3 2025 | 37% | +3 points |
| Q2 2025 | 37% | -1.5 points |
| Q1 2025 | 37% | -0.6 points |
| Q4 2024 | 35% | -3.3 points |
CPRT has the edge over CAT on profitability, with a higher operating margin.
CAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +19% |
| Q2 2026 | $3.8B | +47% |
| Q1 2026 | $1.1B | +97% |
| Q4 2025 | $2.7B | +0.1% |
| Q3 2025 | $3.1B | -1.5% |
| Q2 2025 | $2.6B | -4.2% |
| Q1 2025 | $579M | -63% |
| Q4 2024 | $2.7B | -22% |
CAT generated $11.3B in free cash flow over the past year, up 26% from the year before.
CPRT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $278.7M | -21% |
| Q2 2026 | $503.3M | -20% |
| Q1 2026 | $57.9M | +1330% |
| Q4 2025 | $427.2M | +74% |
| Q3 2025 | $350.8M | +16% |
| Q2 2025 | $630.4M | +54% |
| Q1 2025 | $4M | -90% |
| Q4 2024 | $245.5M | +15% |
CPRT has the edge over CAT on cash flow, with more consistent year-over-year improvement.
CAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.6M shares |
| 1 year | -2.1% | -9.9M shares |
| 3 years | -10% | -51.7M shares |
| 5 years | -16% | -86.7M shares |
| Available history | -19% | -107M shares |
CAT has 461M diluted shares, down 2.1% from a year ago, with $8.1B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.2B |
| Q2 2026 | $1.5B |
| Q1 2026 | $5B |
| Q4 2025 | $340M |
| Q3 2025 | $362M |
| Q2 2025 | $828M |
| Q1 2025 | $3.7B |
| Q4 2024 | $640M |
CAT spent $8.1B buying back its own shares over the past year, up 47% from the year before.
CPRT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +14.1M shares |
| 1 year | -2.1% | -20.7M shares |
| 3 years | -1% | -9.8M shares |
| 5 years | -0.4% | -4.3M shares |
| Available history | +0.2% | +2.2M shares |
CPRT has 957M diluted shares, down 2.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1,000 |
| Q2 2026 | $1.4B |
| Q3 2020 | — |
| Q2 2020 | — |
CAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | 1.6x | Healthy |
CAT has more cash than debt.
CPRT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.0x | Net Cash |
| Q2 2026 | -1.8x | Net Cash |
| Q1 2026 | -2.8x | Net Cash |
| Q4 2025 | -2.7x | Net Cash |
| Q3 2025 | -1.5x | Net Cash |
| Q2 2025 | -1.3x | Net Cash |
| Q1 2025 | -1.8x | Net Cash |
| Q4 2024 | -2.1x | Net Cash |
CPRT has the edge over CAT on leverage, with a lower net debt burden relative to earnings.
CAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.7 | Neutral |
| Stochastic | 6.7 | Oversold |
CAT's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
CPRT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.4 | Neutral |
| Stochastic | 63.3 | Neutral |
CPRT's weekly RSI is 53 (neutral) and its Stochastic is 63 (neutral).
CAT PE vs Industrials Sector
| Metric | CAT | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 24x | 1.3% below |
| PE % | 69 | 58 | 11 pts above |
CAT is trading at 24x earnings, in line with the Industrials sector's median of 24x.
CPRT PE vs Industrials Sector
| Metric | CPRT | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 24x | 14% below |
| PE % | 7 | 58 | 51 pts below |
CPRT has the edge over CAT on valuation relative to its sector.
CAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $709.0 | 15% below |
| 20 week MA | $797.0 | 24% below |
| 50 week MA | $771.3 | 22% below |
| 100 week MA | $586.7 | 3.2% above |
| 200 week MA | $443.1 | 37% above |
CAT has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 37% above its 200-week average.
CPRT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 9.9% above |
| 20 week MA | $29.8 | 7.3% above |
| 50 week MA | $33.3 | 3.8% below |
| 100 week MA | $42.3 | 24% below |
| 200 week MA | $45.1 | 29% below |
CPRT has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 29% below its 200-week average.
CAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $148.3 | $179.6 | +21% |
| 2021 | $179.6 | $206.2 | +15% |
| 2022 | $206.2 | $239.9 | +16% |
| 2023 | $239.9 | $295.7 | +23% |
| 2024 | $295.7 | $364.9 | +23% |
| 2025 | $364.9 | $583.0 | +60% |
| 2026 YTD | $583.0 | $605.3 | +3.8% |
CAT has the edge over CPRT on returns for 2026, with the stronger performance.
CPRT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $22.7 | $30.9 | +36% |
| 2021 | $30.9 | $36.5 | +18% |
| 2022 | $36.5 | $30.3 | -17% |
| 2023 | $30.3 | $49.0 | +62% |
| 2024 | $49.0 | $58.5 | +19% |
| 2025 | $58.5 | $39.3 | -33% |
| 2026 YTD | $39.3 | $32.0 | -19% |
CPRT has finished higher in four of the last six years. It's down 19% so far in 2026.